Guardant Health, Inc. (NASDAQ:GH) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Guardant Health, Inc. (NASDAQ:GH) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $36.83.

Several research firms have issued reports on GH. Jefferies Financial Group began coverage on Guardant Health in a research note on Monday, June 3rd. They issued a “buy” rating and a $32.00 price target on the stock. Stephens reissued an “overweight” rating and issued a $44.00 price target on shares of Guardant Health in a research note on Friday, May 24th. The Goldman Sachs Group dropped their price target on Guardant Health from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, April 15th. Craig Hallum began coverage on Guardant Health in a research note on Wednesday, April 24th. They issued a “buy” rating and a $28.00 price target on the stock. Finally, Canaccord Genuity Group lifted their price target on Guardant Health from $30.00 to $38.00 and gave the company a “buy” rating in a research note on Tuesday, June 4th.

Guardant Health Stock Down 0.6 %

NASDAQ:GH opened at $28.88 on Monday. Guardant Health has a 12-month low of $15.81 and a 12-month high of $41.06. The company has a quick ratio of 5.66, a current ratio of 5.95 and a debt-to-equity ratio of 16.70. The firm has a market capitalization of $3.53 billion, a P/E ratio of -7.37 and a beta of 1.15. The stock’s fifty day simple moving average is $24.98 and its 200-day simple moving average is $22.94.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, May 9th. The company reported ($0.94) earnings per share for the quarter, hitting the consensus estimate of ($0.94). The firm had revenue of $168.49 million for the quarter, compared to analyst estimates of $150.51 million. Guardant Health had a negative return on equity of 246.47% and a negative net margin of 76.34%. Equities research analysts expect that Guardant Health will post -3.31 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GH. Baillie Gifford & Co. acquired a new position in Guardant Health during the fourth quarter valued at approximately $167,137,000. Capital International Investors increased its holdings in shares of Guardant Health by 36.7% during the fourth quarter. Capital International Investors now owns 4,001,803 shares of the company’s stock worth $108,249,000 after buying an additional 1,074,452 shares in the last quarter. Norges Bank acquired a new position in shares of Guardant Health during the fourth quarter worth $25,520,000. Cadian Capital Management LP acquired a new position in shares of Guardant Health during the fourth quarter worth $19,206,000. Finally, Mitsubishi UFJ Trust & Banking Corp acquired a new position in shares of Guardant Health during the first quarter worth $8,300,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.